Chemotherapy Risks in Small Cell Lung Cancer
Author Information
Author(s): L. Morittul, H.M. Earl, R.L. Souhamil, C.M. Ash, J.S. Tobias, D.M. Geddes, P.G. Harper, S.G. Spiro
Primary Institution: University College and Middlesex School of Medicine
Hypothesis
What clinical and biochemical factors are associated with early mortality in patients undergoing chemotherapy for small cell lung cancer?
Conclusion
Patients with clinical hepatomegaly and poor performance status are at a significantly higher risk of early death during chemotherapy.
Supporting Evidence
- 71 of 610 patients died in the first 3 weeks of chemotherapy.
- Patients with clinical hepatomegaly had a significantly higher risk of early death.
- Poor performance status was strongly predictive of early mortality.
Takeaway
Some patients with small cell lung cancer can get very sick from chemotherapy, especially if they have liver problems or are not feeling well to begin with.
Methodology
The study analyzed clinical and biochemical parameters of patients who died early during chemotherapy compared to controls who did not.
Potential Biases
Potential underreporting of chemotherapy-related deaths as patients may be considered to have died from cancer.
Limitations
The study may not account for all variables affecting early mortality, and the data is based on a specific chemotherapy regimen.
Participant Demographics
Patients were primarily adults with small cell lung cancer, median age 64, with a mix of genders.
Statistical Information
P-Value
<0.00001
Want to read the original?
Access the complete publication on the publisher's website